Clinical trial
Efficacy and Safety of 1% Atropine "5+3" Regimen in Children and Adolescents Controlling Myopia
NCT05448989 is registered in ClinicalTrials.gov with Shanghai Eye Disease Prevention and Treatment Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of 1% Atropine "5+3" Regimen in Children and Adolescents Controlling Myopia
- Lead sponsor
- Shanghai Eye Disease Prevention and Treatment Center
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- January 1, 2022
- Completion date
- December 31, 2024
- Enrollment
- 192 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.